HOME >> BIOLOGY >> NEWS
Five Spanish hospitals in international phase III trial with H5N1 influenza pandemic vaccine

Both governments and the scientific community are mobilised to face the threat of a possible pandemic provoked by avian influenza. Whereas there is no need to alarm the population, we must design tools in order to fight influenza in case it develops. According to historical data and to the high genetic variability of influenza virus, the development of this pandemic is only a matter of time and that the appropriate circumstances are given. The H5N1 virus, which affects the European fowl, has already evidenced that it could successfully break the human barrier. This is the reason why H5N1 is the best candidate to establish the bases of the development of pandemic vaccines. Five large national hospitals will participate in the first study with a H5N1 influenza pandemic vaccine held in Spain. Our specialists are working in an international study, with the participation of 7 countries, in order to assess the possible side effects and immunogenicity of this vaccine, developed by GlaxoSmithKline (GSK), in individuals over 18 years.

A total of 5,052 individuals will participate in this study, 1,500 of which will be recruited in Spain. The five Spanish centres are Hospital 12 de Octubre, Hospital Clnico San Carlos and Hospital de La Princesa in Madrid, and the centres Hospital Vall d'Hebrn and Hospital Clnic in Barcelona. People participating in the study will be randomly separated into two groups: 75% will receive two doses of influenza vaccine, and 25% will receive a dose of conventional influenza vaccine and a dose of placebo. The second dose will be administrated after 21 days after the first medical examination, and during the study, two more examinations will have place (days 43 and 180) and a telephone check (day 51). In 10% of volunteers, blood tests will be made in order to analyse the immune response triggered by the vaccine. Furthermore, participants will fill in a monitoring card during the week after the administration of each dose, where the potential
'"/>

Contact: lex Argem
aargemi@clinic.ub.es
34-93-227-5700
IDIBAPS - Institut d'Investigacions Biomdiques August Pi i Sunyer
4-May-2006


Page: 1 2 3

Related biology news :

1. USP 30-NF 25 in English and Spanish now available
2. Spanish scientists reveal dynamic map of proteins
3. New possibilities for flu antiviral and vaccine research emerge from Spanish flu virus
4. Spanish forest fire aftermath surveyed by Envisat
5. Study identifies risk factors for spread of respiratory infections in hospitals
6. Space technology to help hospitals contain spread of avian flu infection
7. American buffalo slaughter fueled by international trade
8. CRESIB coordinates an international consortium to fight malaria caused by Plasmodium vivax
9. 2 MSU professors spearhead international water project
10. Nature surrenders flowery secrets to international team
11. Fibers are center stage at international conference

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2020)... ... March 02, 2020 , ... Nominations are now being ... by the Security Industry Association (SIA) and SecureIDNews and co-presented ... in Security Forum . The recipients of this year’s Women in Biometrics Awards will ...
(Date:2/28/2020)... ... February 26, 2020 , ... ... its patent-pending Rebound PRP™ and Rebound PRF® devices are now available to ... generation of regenerative medical devices, that will provide the most affordable, easiest ...
(Date:2/28/2020)... , ... February 27, 2020 ... ... (VIC), has formed Filtravate, its newest portfolio company. Established to develop and ... technology exclusively licensed from New Mexico State University (NMSU). The patent-pending technology ...
Breaking Biology News(10 mins):
(Date:3/27/2020)... ... ... iFirst Medical Technologies, Inc., a leader in handheld diagnostic devices, announced today that ... grave danger to public health here in the U.S. and around the globe," said ... and on-the-spot results promise to slow the spread and save human lives." , iFirst ...
(Date:3/13/2020)... ... March 12, 2020 , ... Today, DuPont Nutrition & ... Center (APC), a pioneer in the field of microbiome science, which focuses on ... in human health, based at University College Cork and Teagasc Moorepark. , Representatives ...
(Date:3/10/2020)... ... March 10, 2020 , ... ... chain biopharmaceutical engineering firm, is pleased to announce the addition of Carson ... medical device qualification and validation in the biopharmaceutical cold chain. He provides ...
(Date:3/4/2020)... WASHINGTON (PRWEB) , ... March 04, 2020 , ... This ... Exhibition in Orlando, FL. The company will showcase both expanded and emerging offerings that ... HIMSS 2020 is designed to be comprehensive, timely, and engaging. From ...
Breaking Biology Technology:
Cached News: